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Adenovirus-mediated virotherapy is one of the promising therapeutic approaches for glioma treatment.
However, its replication efﬁciency and speciﬁcity still failed to meet the requirements for clinical
treatment. To improve the anti-tumor activity and speciﬁcity of oncolytic adenoviruses (OA), we applied
multiple miRNA response elements (MREs) of miR-124, miR-128, miR-146b and miR-218, whose
expressions were downregulated in glioma cells, to enable OA to be speciﬁc to glioma. Adenoviral
E1A protein regulated by these 4 MREs (OA-4MREs) was shown to be highly expressed in glioma cells,
but not in normal cells. The selective E1A expression led to glioma-speciﬁc replication and cytotoxicity of
OA-4MREs. Animal experiments also showed that OA-4MREs exhibited improved anti-tumor activities
for both subcutaneous and intracranial glioma xenografts, without signiﬁcant toxicity to normal brain
and liver tissues. Collectively, we demonstrated that oncolytic adenovirus, whose replication was
regulated by MREs, may be promising biological agents for glioma treatment.
& 2014 Elsevier Inc. All rights reserved.
Introduction
As the most common intracranial neoplasm, malignant glioma
has high invasiveness, metastasis and recurrence (Reardon et al.,
2011). So far, traditional treatments have limited outcome, includ-
ing surgery, chemotherapy and radiotherapy. Thus, novel
therapeutic strategies are urgently required for efﬁcient glioma
treatment.
Oncolytic adenovirus (OA, also known as conditionally replica-
tive adenovirus, CRAd) is a prospective biological agent against
various types of cancer (Alvarez-Breckenridge et al., 2012; Chen et
al., 2011; Fulci et al., 2007; Post et al., 2003; Xu et al., 2012). OA
displays a higher anti-tumor activity than replication-incompetent
(E1A-null) adenoviruses, mainly due to its remaining replication in
cancer cells and continuous infection of surrounding tumor cells.
However, natural adenoviruses also have cytotoxicity to normal
cells, thereby limiting their clinical application for cancer therapy.
To confer OA with speciﬁcity to cancer cells, researchers have
developed many strategies to enable adenoviruses to discriminate
between neoplastic and normal cells for selective replication.
Onyx-015 (deletion of 55 kDa protein in E1B region) is the ﬁrst
attempt to generate a cancer-speciﬁc adenovirus. However, its
speciﬁcity is still not satisfactory, since its replication is greatly
impaired after modiﬁcation (Su et al., 2004). Similarly, 24 bp
deletion in CR2 domain of E1A region ensures selective replication
of adenoviruses in cancer cells, but weakens their replication
efﬁciency (Zhang et al., 2007). Human telomerase reverse tran-
scriptase (TERT) is found to be overexpressed in a variety of
cancers, and thus, is widely employed to construct tumor-
speciﬁc viral vectors. TERT promoter is also used to regulate E1A
activity of adenoviruses in cancer cells. However after this mod-
iﬁcation, replication of OA is usually weaker than wild type
adenovirus, whose E1A expression was driven by its original
promoter (He et al., 2011; Luo et al., 2008; Zhang et al., 2007).
Low replication efﬁciency of the current OAs urge scientists to
search for novel strategies to improve OA systems.
miRNAs are found to be differentially expressed between
cancerous and normal tissues. Downregulated expression proﬁle
of speciﬁc miRNAs raises the possibility of utilizing these miRNAs
to enable adenovirus to speciﬁcally replicate in cancer cells, such
as malignant glioma (Gomez-Manzano and Fueyo, 2010). So far,
there are no reports about constructing glioma-speciﬁc oncolytic
adenoviruses by utilizing differential expression proﬁle of miRNAs
between glioma and normal cells.
In this study, we selected let7 and 19 other microRNAs
(abbreviated as miR), whose expressions have been conﬁrmed to
be downregulated in glioma samples and/or cell lines, including
miR-7 (Kefas et al., 2008; Silber et al., 2008; Skalsky and Cullen,
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2011), miR-16, miR-19a, miR-20a (Malzkorn et al., 2010), miR-26b
(Wu et al., 2011), miR-124 (Silber et al., 2008; Skalsky and Cullen,
2011), miR-128 (Godlewski et al., 2008; Skalsky and Cullen, 2011),
miR-129, miR-137 (Silber et al., 2008), miR-139 (Skalsky and Cullen,
2011), miR-140 (Malzkorn et al., 2010), miR-146b (Xia et al., 2009),
miR-181b (Conti et al., 2009), miR-184 (Malzkorn et al., 2010), miR-
205 (Yue et al., 2012), miR-218 (Rao et al., 2010; Silber et al., 2008;
Skalsky and Cullen, 2011), miR-219-5p (Rao et al., 2010), miR-328
(Malzkorn et al., 2010) and miR-451 (Nan et al., 2010), to evaluate
the feasibility and effectiveness of their miRNA response elements
(MREs) to regulate the speciﬁc replication of OA in glioma cells.
Results
Differential miRNA expression proﬁle between glioma and normal
brain cells
First of all, let7 and 19 other microRNAs (miRNAs), whose
expressions have been reported to be downregulated in glioma
samples and/or cell lines, were listed as candidates to ensure
glioma-speciﬁcity. To experimentally conﬁrm the differential
expression proﬁles of these miRNAs, we investigated their expres-
sions in 11 glioma tissues from patients. Inconsistent with pre-
vious reports, miR-19a abundance was not reduced, but increased
in malignant glioma tissues, compared with their corresponding
noncancerous brain tissues. Also, there were no signiﬁcant differ-
ences in the expressions of miR-16, miR-20a, miR-184 and miR-328
between cancerous and noncancerous samples. However, other
miRNAs were all found to be underexpressed in glioma tissues
(Fig. 1A).
miRNA response elements (MREs) of miR-124, miR-128, miR-146b
and miR-218 were effective regulators for glioma-speciﬁc gene
expression
To evaluate if these miRNAs could be used for glioma-speciﬁc
expression of exogenous genes, we transfected U-87 MG glioblas-
toma cell line and normal embryonic astrocytes with a series of
luciferase reporter plasmids, whose luciferase expressions were
modulated by MREs of these miRNAs. The results on U-87 MG cells
showed that luciferase expressions were suppressed by more than
20% when MREs of miR-7, miR-19a, miR-20a, miR-26b, miR-139,
miR-184, miR-205, miR-219-5p, miR-328 and let-7 were inserted,
excluding the possibility that these MREs can be used to ensure
high expression of E1A in glioma cells during subsequent adeno-
virus modiﬁcation. In contrast, MREs of other miRNAs only slightly
affected luciferase activity in glioma cells (Fig. 1B).
The data on normal embryonic astrocytes indicated that
luciferase expressions were signiﬁcantly suppressed when these
MREs were used, except that of miR-16. Furthermore, the applica-
tion of MREs of miR-124, miR-128, miR-139, miR-146b, miR-181b,
miR-218 and miR-219-5p suppressed luciferase expression by more
than 70% (Fig. 1C).
Finally, MREs were selected for glioma-speciﬁc expression of
exogenous genes according to the following criteria. (1) miRNAs
should be downregulated by more than 50% in glioma tissues
compared with noncancerous brain tissues. (2) The inhibitory
effect of MRE on luciferase expression should be lower than 20%
in U-87 MG glioma cells. (3) MRE should suppress the luciferase
activity by more than 70% in normal embryonic astrocytes. Based
on the above standards, the MREs of miR-124, miR-128, miR-146b
and miR-218 were selected to be used for glioma-speciﬁc exogen-
ous expression.
Combination of the MREs of miR-124, miR-128, miR-146b and miR-
218 conferred higher glioma-speciﬁcity than single MREs
Although the application of MREs of miR-124, miR-128, miR-
146b and miR-218 alone suppressed luciferase expression by 75–
85% in normal embryonic astrocytes, there was still a possibility
that 15–25% of remaining expressions of exogenous genes were
sufﬁcient to affect cell survival and/or function. To further improve
the speciﬁcity of MRE-based regulation, we simultaneously uti-
lized these 4 MREs to modulate luciferase expression (Fig. 2A). The
results demonstrated that combination of MREs of miR-124, miR-
128, miR-146b and miR-218 suppressed luciferase expression by
97.8% and 98.7% in two separate primary normal embryonic
astrocytes, respectively, while single application of these MREs
lead to only 70.9–81.7% and 73.6–77.6% reduction in luciferase
expressions in the same cells, respectively (Fig. 2B). These data
indicated that application of multiple MREs had an additive
suppressing effect on exogenous gene expression.
To test if the combination of 4 MREs affected gene expression in
glioma cells, luciferase reporter assays were also performed on U-
87 MG and primary glioma cells. Luciferase activity was found to
be higher than 80% when pluc-4miRNAs were transfected into
these cells, although its expression level is slightly lower com-
pared with pluc-miR-124, pluc-miR-128, pluc-miR-146b or pluc-
miR-218 alone (Fig. 2B).
Collectively, combined application of 4 MREs enabled exogen-
ous gene expression to have higher glioma-speciﬁcity, without
signiﬁcantly affecting its expression level in glioma cells.
MRE-regulated exogenous gene expression depended on the level
of miR-124, miR-128, miR-146b and miR-218
To conﬁrm the regulation of miR-124, miR-128, miR-146b and
miR-218 on exogenous gene expression under their MREs, lucifer-
ase assays were performed in the pluc-4miRNAs-transfected cells
after the level of these miRNAs was changed. The expression
of endogenous miR-124, miR-128, miR-146b and miR-218 was
suppressed by 37.3–54.7% in normal embryonic astrocytes by
the mixture of these 4 miRNA inhibitors (Fig. 3A). Under this
condition, luciferase expression was signiﬁcantly upregulated in
pluc-4miRNAs-transfected cells (Fig. 3B). Consistently, luciferase
expression was greatly decreased in the pluc-4miRNAs-transfected
U-87 MG cells, in which miR-124, miR-128, miR-146b and miR-218
levels were elevated by the treatment of mixed 4 miRNA mimics
(Fig. 3C and D).
These data demonstrated that exogenous gene expression
regulated by MREs of miR-124, miR-128, miR-146b and miR-218
depended on the levels of these 4 miRNAs in the transfected cells.
Expression level of miR-124, miR-128, miR-146b and miR-218
controlled the replication of MRE-regulated adenovirus
A recombinant oncolytic adenovirus (OA-4MREs) was con-
structed by inserting MREs of miR-124, miR-128, miR-146b and
miR-218 immediately following E1A-encoding open reading frame
(ORF), allowing the corresponding miRNAs to suppress E1A
expression in normal cells (Fig. 3E). In normal embryonic astro-
cytes with high expression levels of the 4 miRNAs, E1A protein and
mRNA expression was greatly suppressed when the cells were
infected with OA-4MREs. However, the treatment of miRNA
inhibitors restored E1A expression in OA-4MREs-infected cells
(Fig. 3F and H). Consistently, transfection of miRNA mimics
signiﬁcantly reduced the expression of E1A protein and mRNA in
U-87 MG cells, in which endogenous levels of miR-124, miR-128,
miR-146b and miR-218 were low (Fig. 3G and I).
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Fig. 1. miRNA response elements (MREs) of miR-124, miR-128, miR-146b and miR-218 were effective regulators for glioma-speciﬁc gene expression. (A) Expression levels of
different miRNAs were detected in glioma and corresponding noncancerous brain tissues. miRNA level in the corresponding noncancerous brain tissues was considered as
standard and U6 was selected as the endogenous reference. Means7SD of three independent experiments are shown. (B and C) Luciferase constructs containing MREs of
these miRNAs were transfected into U-87 MG cells and normal astrocytes. Relative luciferase activity in the cells transfected with pluc was considered as standard.
Means7SD of three independent experiments are shown.
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Subsequently, replication of MRE-regulated adenovirus was eval-
uated both in U-87 MG cells and normal embryonic astrocytes. OA-
4MREs produced much lower titer of progenies in normal cells than
wild type adenovirus (Ad-WT), and treatment of miRNA inhibitors
increased progeny production of OA-4MREs (Fig. 3J). In U-87MG cells,
OA-4MREs had a similar yield of virus progeny to Ad-WT. However,
increasing the abundance of the 4 miRNAs lead to a great reduction in
the replication of the MRE-regulated adenovirus (Fig. 3K).
These data showed that E1A expression and replication of
MRE-regulated adenovirus were both dependent on the levels of
miR-124, miR-128, miR-146b and miR-218.
The replication and cytotoxicity of MRE-regulated adenovirus was
suppressed in the cells derived from normal tissue
E1A expression was subsequently estimated in normal embryonic
astrocytes infected by OA-4MREs, compared with Ad-WT and Onyx-
015. OA-4MREs had no detectable E1A expression in the astrocytes,
while there was high level of E1A proteins both in Ad-WT- and Onyx-
015-infected cells (Fig. 4A). qPCR assay also conﬁrmed the differential
expression of E1A mRNA in the cells infected with indicated adeno-
viruses (Fig. 4B). Accordingly, OA-4MREs also had lower yield of
progenies in the two primary astrocytes, compared with Onyx-015
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Fig. 2. Combined application of MREs of miR-124, miR-128, miR-146b and miR-218 resulted in higher glioma-speciﬁcity than the usage of single MREs. (A) Schematic
illustration of the involved vectors in the luciferase assays. Two copies of MREs of miR-124, miR-128, miR-146b or/and miR-218 were immediately inserted following the
luciferase-encoding regions. (B and C) Luciferase expression was quantiﬁed in normal embryonic astrocytes and glioma cells transfected with luciferase reporter plasmids.
Relative luciferase activity in the cells transfected with pluc was considered as standard. Means7SD of three independent experiments are shown.
Fig. 3. Adenoviral E1A expression regulated by the 4 MREs was strictly dependent on the levels of their corresponding miRNAs. (A) Synthetic inhibitors of miR-124, miR-128,
miR-146b or miR-218 were mixed and transfected into normal embryonic astrocytes (40 nM). Expression levels of these miRNAs were assessed by qPCR with U6 as
endogenous reference and were shown as values relative to control groups. Means7SD of three independent experiments are shown. (B) Co-transfection of embryonic
astrocytes with indicated constructs and mixed miRNA inhibitors or controls (40 nM). 48 h later, luciferase expression was evaluated. Relative luciferase activity in the cells
transfected with pluc and control inhibitors was considered as standard. Means7SD of three independent experiments are shown. (C) Synthetic mimics ofmiR-124,miR-128,
miR-146b ormiR-218 (40 nM) were mixed and transfected into U-87 MG cells. Expression levels of these miRNAs were assessed by qPCR with U6 as the endogenous reference
and were shown as values relative to control groups. Means7SD of three independent experiments are shown. (D) Co-transfection of U-87 MG cells with indicated
constructs and mixed miRNA mimics or controls (40 nM). 48 h later, luciferase expression was evaluated. Relative luciferase activity in the cells transfected with pluc and
control inhibitors was considered as standard. Means7SD of three independent experiments are shown. (E) Schematic illustration of the involved adenoviruses in the
manuscript. Wild type serotype 5 of adenovirus (Ad-WT) was used as control. OA-4MREs has MREs of miR-124, miR-128, miR-146b and miR-218 inserted immediately
following E1A gene. E1B 55 kDa protein in Onyx-015 was completely deleted. (F) Normal astrocytes were transfected with mixed miRNA inhibitors or control (40 nM),
followed by indicated adenovirus infection (5 MOI). 48 h later, E1A protein level was determined by immunoblotting assay and GAPDH was selected as the endogenous
reference. (G) U-87 MG cells were transfected with mixed miRNA mimics or control (40 nM), followed by indicated adenovirus infection (5 MOI). 48 h later, E1A protein level
was also determined with GAPDH as the endogenous reference. (H and I) E1A mRNA expression was detected using qPCR methods in the miRNA inhibitor-treated normal
astrocytes and miRNA mimics-treated U-87 MG cells after infection of Ad-WT and OA-4MREs (5 MOI). GAPDHwas selected as the endogenous reference. Means7SD of three
independent experiments are shown. (J and K) Progeny production of the normal astrocytes and U-87 MG cells with indicated treatments were evaluated by replication
assays. Progeny yields are presented as pfu/ml. Means7SD of three independent experiments are shown.
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(Fig. 4C). Viability analysis indicated that OA-4MREs only exerted a
slight cytotoxicity to normal astrocytes, at the dose of up to 100 MOI
(Fig. 4D). However, the survival of these astrocytes was affected by the
infection of Onyx-015 of higher than 20 MOI (Fig. 4D).
Besides astrocytes, normal cells originating from other tissues
were also investigated for the speciﬁcity of OA-4MREs replication
and cytotoxicity. Expression levels of miR-124 and miR-128 were
both signiﬁcantly upregulated in HCN-2 neural cells, HUV-EC-C
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endothelial cells, and L-02 liver cells, in comparison with glioma
samples from patients (Fig. 4E). HCN-2 and HUV-EC-C cells also
had signiﬁcantly higher copies of miR-146b and miR-218 than
glioma tissues (Fig. 4E). Compared with Ad-WT, the replication of
OA-4MREs was highly suppressed in these normal cells (Fig. 4F).
Similar to the data on normal astrocytes, MRE-regulated adeno-
virus also produced lower titers of progenies than Onyx-015 in
HCN-2, HUV-EC-C and L-02 cells (Fig. 4F). OA-4MREs did not
reduce the viability of these normal cells, whereas Onyx-015
showed cytotoxicity at high MOIs (Fig. 4G).
The above results suggested that replication of OA-4MREs was
signiﬁcantly suppressed in normal cells, compared with Ad-WT
and Onyx-015. OA-4MREs had no obvious cytotoxicity to
normal cells.
OA-4MREs efﬁciently replicated in glioma cells and exerted
a survival-reducing activity
Anti-tumor capacity of OA-4MREs was investigated using both
glioma cell lines and primary glioma cells. E1A expressions were
shown to be similar between OA-4MREs- and Ad-WT-infected U-87
MG cells both on protein and mRNA levels (Fig. 5A and B).
Replication assay showed that OA-4MREs produced similar amount
of progenies to Ad-WT in U-87 MG, U-251 MG, U-371 MG and
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Fig. 4. OA-4MREs had no cytotoxicity to normal cells originating from brain and other tissues. (A) Normal embryonic astrocytes were infected with Ad-WT, OA-4MREs and
Onyx-015 (5 MOI). 48 h later, E1A protein level was determined by immunoblotting assay and GAPDH was selected as the endogenous reference. (B) E1A mRNA expression
was detected using qPCR methods in adenovirus-treated normal astrocytes (5 MOI). GAPDH was selected as the endogenous reference. Means7SD of three independent
experiments are shown. (C) Progeny production of the normal astrocytes treated with indicated adenoviruses (5 MOI) were evaluated by replication assays. Progeny yields
are presented as pfu/ml. Means7SD of three independent experiments are shown. (D) Cell viability was evaluated on embryonic astrocytes infected with different
concentrations of adenoviruses by MTT assays on day 7 after infection. Means7SD of three independent experiments are shown. (E) Expression levels of miR-124, miR-128,
miR-146b and miR-218 were detected in HCN-2, HUV-EC-C, and L-02 cells and U6 was selected as the endogenous reference. Means7SD of three independent experiments
are shown. (F) Progeny production of HCN-2, HUV-EC-C and L-02 cells treated with indicated adenoviruses (5 MOI) were evaluated by replication assays. Progeny yields are
presented as pfu/ml. Means7SD of three independent experiments are shown. (G) Cell viability of HCN-2, HUV-EC-C and L-02 cells was tested on day 7 after infection of
different concentrations of adenoviruses evaluated by MTT assays. Means7SD of three independent experiments are shown.
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M059J cells (Fig. 5C). Interestingly, this MRE-regulated oncolytic
adenovirus had higher production of progenies than Onyx-015 in
glioma cells (Fig. 5C). OA-4MREs had an anti-tumor activity that is
similar to Ad-WT on the tested glioma cell lines (Fig. 5D). Also, the
survival-reducing effect of OA-4MREs on glioma cells was stronger
than Onyx-015 (Fig. 5D).
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Fig. 5. OA-4MREs potently reduced the survival of glioma cells. (A) U-87 MG cells were infected with Ad-WT, OA-4MREs and Onyx-015 (5 MOI). 48 h later, E1A protein level
was determined and GAPDH was selected as the endogenous reference. (B) E1A mRNA expression was also detected using qPCR methods in adenovirus-treated U-87 MG
cells. GAPDH was selected as the endogenous reference. Means7SD of three independent experiments are shown. (C) Progeny production of U-87 MG, U-251 MG, U-371 MG
and M059J cells treated with indicated adenoviruses (5 MOI) were evaluated by replication assays. Progeny yields are presented as pfu/ml. Means7SD of three independent
experiments are shown. (D) Cell viability was evaluated on U-87 MG, U-251 MG, U-371 MG and M059J cells infected with different concentrations of adenoviruses on day
7 by MTT assays. Means7SD of three independent experiments are shown. (E) Progeny production of two primary glioma cells treated with indicated adenoviruses were
evaluated by replication assays. Progeny yields are presented as pfu/ml. Means7SD of three independent experiments are shown. (F) Cell viability of two primary glioma
cells, which were infected with different concentrations of adenoviruses, was evaluated by MTT assays. Means7SD of three independent experiments are shown.
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Consistent with the data on glioma cell lines, OA-4MREs also
replicated more efﬁciently than Onyx-015 in primary glioma cells
from the patients (Fig. 5E). Its cytotoxicity to these primary cells
was also higher than Onyx-015 (Fig. 5F).
Therefore, OA-4MREs retained a high replication ability in
glioma cells and greatly suppressed their viability.
OA-4MREs suppressed the growth of glioma xenograft
without toxicity to normal tissues
We further tested the anti-glioma activity of OA-4MREs on
glioma xenograft in different mouse models. In a subcutaneous
xenograft model, intratumoral injection of OA-4MREs inhibited
the growth of both U-87 MG- and primary glioma-derived tumors.
The therapeutic outcome of OA-4MREs is similar to that of Ad-WT
and there was no signiﬁcant difference in the anti-tumor capacity
between OA-4MREs and Ad-WT (Fig. 6A and B). In contrast, Onyx-
015 was shown to reduce the growth of tumors by no greater than
40% (Fig. 6A and B).
In an orthotopic U-87 MG xenograft model, OA-4MREs treat-
ment markedly prolonged the survival of tumor-bearing mice
(mean7SD, 54.6776.25 days) (Fig. 6C). Onyx-015 had only a
limited survival-prolonging effect on mice (mean7SD,
20.0075.18 days), compared with the PBS (mean7SD,
14.0075.51 days) (Fig. 6C). Ad-WT also prolonged the survival
of tumor-bearing mice (47.00711.40 days), although its effect is
moderately weaker than OA-4MREs (P¼0.188) (Fig. 6C). Strong
E1A staining indicated high proliferation in tumor sections both
from Ad-WT- and OA-4MREs-treated mice. Weak E1A staining
showed that Onyx-015 had relatively limited proliferation ability
(Fig. 6D). Importantly, there was no obvious E1A staining in the
brain section from OA-4MREs-injected mice. In contrast, extensive
E1A expression was easily observed in normal brain derived from
the animals treated with Ad-WT and Onyx-015 (Fig. 6D).
To evaluate the hepatotoxicity induced by adenovirus treat-
ment, we collected the blood from another 4 groups of tumor-free
mice systemically injected with Ad-WT, PBS, Onyx-015 and OA-
4MREs. The results showed that both Ad-WT and Onyx-015
treatment signiﬁcantly increased the level of liver damage indi-
cator, alanine aminotransferase (ALT), in the serum. In contrast,
there was no obvious difference in serum level of ALT between
PBS- and OA-4MREs-treated mice (Fig. 6E). Immunohistological
analysis indicated that there was no obvious E1A staining in the
liver section from OA-4MREs-injected mice. In contrast, E1A was
widely expressed in normal liver tissues from the mice injected
with Ad-WT or Onyx-015 (Fig. 6F).
The above data demonstrated that OA-4MREs were able to
suppress the growth of glioma in vivo, but not damaged normal
tissues of the treated animal.
Discussion
We compared miRNA expression proﬁles of glioma and its
corresponding noncancerous brain tissue. The data showed that
most of the tested miRNAs had signiﬁcantly reduced expression
level in glioma. However, miR-19a level was increased, but not
reduced, in these glioma samples, inconsistent with previous
reports (Malzkorn et al., 2010). The explanation may be that we
used primary glioma for miRNA detection while Malzkorn et al.
studied this miRNA using secondary glioblastoma samples, and
there may be differential expression proﬁle of miR-19a between
the two cases.
As one of the most widely studied tumor-suppressing miRNA,
let-7 expression showed only a moderate reduction in glioma
(approximately 55%) compared with some other miRNAs (miR-124,
miR-128, miR-139, miR-140 and miR-218), which weakened its
feasibility and effectiveness to prevent adenovirus replication from
normal brain cells.
Luciferase reporter assay revealed that 7 MREs suppressed
luciferase expression by more than 70%. The strong inhibitory
activity of these MREs may be due to their enrichments in normal
brain tissues (Cheng et al., 2009; Ciafre et al., 2005; Sempere et al.,
2004). MREs of miR-7, miR-26b, miR-181b, miR-184, miR-205, miR-
328 and let-7 were also found to affect luciferase expression in
glioma cells, which may impair adenovirus replication if applied.
Although these miRNAs were downregulated in glioma cells, the
remaining RNA appeared to suppress exogenous gene expression
to some extent.
Many researchers have modiﬁed adenovirus for its tumor-
speciﬁc replication by inserting MRE of single miRNA to modulate
E1A expression (Cawood et al., 2011; Jin et al., 2011; Leja et al.,
2010). However, adenovirus replication was not effectively sup-
pressed if the selected miRNA was not highly expressed in some
speciﬁc normal cells, thereby causing a nonselective cytotoxicity.
In our study, we simultaneously utilized 4 MREs of different
miRNAs to control E1A expression and viral replication. Our data
veriﬁed a superiority of our strategy over using single MRE to limit
exogenous gene expression in normal tissue-derived cells, show-
ing that application of multiple MREs is a promising strategy to
construct oncolytic adenoviruses with higher speciﬁcity. In fact,
the application of multiple MREs has already been tested for gene
therapy and virotherapy for cancers (Liu et al., 2013; Ylosmaki et
al., 2008).
The expression proﬁles ofmiR-124,miR-128,miR-146b andmiR-
218 in normal cells were also investigated in our studies. Com-
pared with glioma tissue, miR-124 was found to have an elevated
level in neuron, endothelial cells and hepatic cells. Interestingly,
overexpression of miR-124 was able to facilitate reprogramming of
ﬁbroblast to functional neuron (Yoo et al., 2011). It was also
reported that miR-124 had a high expression level in normal liver
tissues (Zheng et al., 2012). miR-128 level was also highly
expressed in these normal cells. In fact, miR-128 was among the
most enriched miRNAs in neuron (Smirnova et al., 2005). Although
miR-146b expression was downregulated in mature neuron, in
comparison with neuronal progenitor cells (Liu et al., 2012), we
demonstrated that its abundance was signiﬁcantly higher in
neuron cells than glioma tissues. The tested normal cells also
had higher expression level of miR-218, which has been shown to
be important for vascularization of retina and enriched in neuron
(Small et al., 2010).
Consistently, OA-4MREs have lower E1A expression and repli-
cation in normal cells than other oncolytic adenoviruses. Viral
replication assays showed that OA-4MREs had only a limited
amount of adenoviral progenies in normal cells, HCN-2, HUV-EC-
C and L-02. Consistently, OA-4MREs had no signiﬁcant cytotoxicity
to the tested normal cells. In animal experiments, OA-4MREs
prolonged animal survival most efﬁciently among the tested
adenoviruses. Liver function evaluation and immunohistological
analysis both showed that MRE-regulated adenoviruses had no
toxicity to normal liver and brain tissues. Therefore, we concluded
that OA-4MREs possessed a high safety and can be further tested
for clinical applications.
qPCR and immunoblotting assay revealed that E1A expression
was almost not affected in OA-4MREs-infected glioma cells. Onyx-
015 has the lowest progeny production in glioma cells among the
tested adenoviruses, because the deletion of E1B 55 kDa protein
greatly decreased the efﬁciency of adenovirus replication. This
reduction in adenovirus replication has also been reported by
other groups (Su et al., 2004).
In future, MREs of other miRNAs can also be used to further
improve the safety of OA. For example,miR-122 is the most abundant
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Fig. 6. OA-4MREs suppressed the growth of glioma xenograft in vivo without damage to normal tissues. (A) Subcutaneous U-87 MG glioma xenograft was established by inoculating
2106 cells into left ﬂanks of male BALB/c nude mice (n¼6). 1109 pfu of Ad-WT, Onyx-015 and OA-4MREs were treated and the tumor volumes were periodically measured.
Means7SD of tumor sizes are shown. The arrows indicate time-points of adenovirus injection. (B) Subcutaneous primary glioma xenograft was established by subcutaneously
injecting 1106 cells into lower right ﬂanks of male BALB/c nude mice (n¼5). 1109 pfu of different adenoviruses were treated and the tumor volumes were periodically measured.
Means7SD of tumor sizes are shown. The arrows indicate time-points of adenovirus injection. (C) Intracranial U-87 MG glioma xenografts were established by injecting 1106 cells
into the forebrain of male BALB/c nude mice (n¼6). 1109 pfu of different adenoviruses were directly injected into the established tumors. The deaths of mice were recorded every
day. The Kaplan–Meier method and the Cox–Mantel log-rank test (two-sided) were used to assess the statistical signiﬁcances of differences in survival time. (D) Histological staining
was performed to detect the expression of E1A, which indicated the proliferation of adenovirus, in the tumor and brain sections from adenovirus-injected mice that bear intracranial
glioma xenografts (200 ). (E) 20 male BALB/c mice (n¼5, no tumor xenograft) were intravenously injected with 1109 pfu of different adenoviruses every other day for ﬁve times.
On day 11, their blood was harvested for the measurement of ALT levels. Means7SD of ALT serum levels are shown. (F) Histological staining was also performed to detect E1A
expression in liver tissue from tumor-free mice systemically injected with adenovirus (200 ).
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miRNA in normal liver cells and acts as a tumor-suppressing miRNA
(Ma et al., 2010). Therefore, MRE of miR-122 can also be applied to
prevent liver cells from the cytotoxicity induced by OA.
Collectively, we constructed a glioma-targeting oncolytic ade-
novirus whose E1A expression was regulated by multiple MREs
and demonstrated that this modiﬁcation retained adenovirus
replication and effectively suppressed glioma growth, and mean-
while, showed a limited cytotoxicity to normal cells. This oncolytic
adenovirus is a promising anti-glioma biological agent and has the
potential to be applied for clinical treatment.
Materials and methods
Cell line cultures
Human glioblastoma cell lines, U-87 MG, U-251 MG, U-373 MG
and M059J, human neuronal cells HCN-2 and human endothelial
cells HUV-EC-C were purchased from American Type Culture
Collection (Manassas, VA). Human normal liver cells L-02, and
human embryonic kidney cells HEK-293 cells were obtained from
Shanghai Cell Collection (Shanghai, China). The cells were all
cultured using DMEM supplemented with 10% of fetal bovine
serum (FBS), 4 mM glutamine, 100 units/ml penicillin, and 100 μg/
ml streptomycin in a 5% CO2 and humidiﬁed atmosphere at 37 1C.
Primary culture/ethics statement
We employed primary cultures derived from malignant glioma
and normal astrocytes in this study. For primary glioma culture,
fresh cancerous tissue was obtained from patients according to
protocols approved by the Ethical Review Board in the Afﬁliated
Hospital of Medical College of Qingdao University (Qingdao,
China). The patients have provided their written informed consent
to participate in this study. All patients underwent surgical
resection of primary glioma at the Department of Neurological
Surgery, The Afﬁliated Hospital of Medical College of Qingdao
University (Qingdao, China). Glioma tissues were cut into small
pieces. The single cell suspension was obtained by mechanical
manipulation. The primary cultures were established initially in
DMEM supplemented with 15% FBS and maintained in DMEM
supplemented with 10% FBS.
For primary astrocyte culture, the samples were obtained from
aborted fetus with informed consent from the pregnant women,
according to the previously published procedures approved by
Ethical Review Board in the Afﬁliated Hospital of Medical College
of Qingdao University (Qingdao, China). The procedures were
brieﬂy described as follows. Brain tissue from anterior fontanel
was cut into pieces with the removal of meninges, followed by
trypsin digestion. The digested cells were ﬁltered with a steel net
and cultured in DMEM supplemented with 15% FBS. GFAP expres-
sion was conﬁrmed by immunoﬂuorescent staining.
Quantitative PCR (qPCR)
For miRNA detection in glioma tissues, fresh cancerous and
noncancerous brain tissues were obtained with written informed
consent from all patients according to protocols approved by the
Ethical Review Board in the Afﬁliated Hospital of Medical College
of Qingdao University (Qingdao, China). All patients underwent
surgical resection of primary glioma at the Department of Neuro-
logical Surgery, The Afﬁliated Hospital of Medical College of
Qingdao University (Qingdao, China).
Total RNA was extracted from glioma and noncancerous brain
tissue with Trizol solution (Sigma-Aldrich, MO). Reverse transcrip-
tion reaction was performed with a TaqMans MicroRNA Reverse
Transcription Kit (Applied Biosystems) following the manufacturer's
instructions. qPCR was performed using TaqMans 2Universal
PCR Master Mix (Applied Biosystems) on CFX96™ Real-Time PCR
Detection System (Bio-Rad Laboratories, CA) supplied with analy-
tical software.
To determine E1A mRNA level in adenovirus-infected cells,
5 MOI of indicated adenoviruses were added to cell cultures. After
48 h, cells were harvested for RNA extraction, followed by being
transcribed into cDNAs using Rever Tra Ace qPCR RT Kit (Toyobo,
Japan) according to the manufacturer's instructions. qPCR was
performed using SYBR premix Ex Taq (Takara) on CFX96™ Real-
Time PCR Detection System (Bio-Rad Laboratories, CA) supplied
with analytical software. The primers used for qPCR are previously
described (He et al., 2011).
Adenovirus construction
Wild type serotype 5 (Ad-WT) and oncolytic adenovirus Onyx-
015 were kindly gifted by Dr. Zhao (General Hospital of Chengdu
Military Area Command of Chinese PLA, Chengdu, China). We
constructed OA-4MREs mainly according to the procedures
described by Jin et al. (2011). Brieﬂy, BstBI and SalI restriction sites
were introduced immediately following adenoviral E1A gene of
pXC1 (Microbix Biosystems Inc., Toronto, Canada), generating
pXC-MREs. A DNA fragment containing 2 copies of miR-124 MREs,
2 copies of miR-128MREs, 2 copies of miR-146bMREs and 2 copies
of miR-218 MREs (TTCGAAACAAACACCCGGCCTGATTCACAACAC-
CAGCTACAAACACCCGGCCTGATTCACAACACCAGCTACAAACACCGA
ACAGGTAGTCTGAACACTGGGACAAACACCGAACAGGTAGTCTGAACA
CTGGGACAAACACCCAAACACCATTGTCACACTCCAACAAACACCC
AAACACCATTGTCACACTCCAGTCGAC) was introduced into pXC-
MREs at the sites of BstBI/SalI to generate pXC-4MREs. The
structure of the recombinant adenovirus was conﬁrmed by DNA
sequencing. pXC-4MREs was co-transfected with pAdEasy into
HEK293 cells. After plague puriﬁcation for three times and PCR-
based identiﬁcation, the adenoviruses were harvested and then
puriﬁed with the CsCl gradient centrifugation. The constructed
adenovirus was designated as OA-4MREs. The titers of the
involved adenoviruses were quantiﬁed with the TCID50 method
on HEK-293 cells and shown as plaque-forming units per milliliter
(pfu/ml). The structures of these adenoviruses are illustrated in
Fig. 3E.
Luciferase reporter construction and assay
The sense and antisense sequences containing 2 copies of
speciﬁc MREs were synthesized, annealed and inserted into the
XhoI and NotI sites of psiCheck2 vectors (Promega, WI) immedi-
ately following the Renilla luciferase gene to construct MRE-
regulated luciferase reporter, which were designated as pluc-
miR-nn.
After transfection of U-87 MG cells and normal embryonic
astrocytes and subsequent 48 h incubation, cells were harvested
and treated with lysis buffer. Fireﬂy and Renilla luciferase activities
were determined with the Dual-Luciferase reporter system (Pro-
mega, WI) following the manufacturer's procedures.
miRNA mimics and inhibitors
mirVana™mimics and inhibitors of miR-124, miR-128, miR-146b
and miR-218 (Life Technologies Invitrogen, Karlsruhe, Germany)
were mixed thoroughly and added to the indicated cells at the
concentration of 40 nM (10 nM for each mimic or inhibitor) using
Lipofectamine™ 2000 (Life Technologies Invitrogen, Karlsruhe,
Germany) according to the instructions. 48 h later, cells were used
for subsequent experiments.
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Immunoblotting assay
Cells were infected with indicated adenoviruses at a MOI of 5.
48 h later, proteins were harvested with M-PERs Mammalian
Protein Extraction Reagent (Thermo Scientiﬁc, IL), separated using
polyacrylamide gel electrophoresis and transferred onto 0.45 μm
nitrocellulose membranes. After being blocked with 5% fat-free
dry milk for 2 h, the membrane was incubated with mouse
monoclonal IgG against adenovirus E1A protein (1:200, Santa Cruz
Biotechnology, CA) for 2 h. Overnight, the membrane was incu-
bated with horseradish peroxidase-conjugated goat polyclonal
antibody against mouse IgG (1:4000, Immunology Consultants
Laboratory, OR) and visualized with SuperSignal West Dura
Extended Duration Substrate (Thermo Scientiﬁc, IL).
Virus replication assay
Cells were infected with indicated adenoviruses at a MOI of 5.
48 h later, cells were harvested and then lysed via freeze and thaw
three times. The titers of viral progenies were quantiﬁed on HEK-
293 cells with the TCID50 method.
Cytotoxicity assay
Adenoviral vectors of indicated MOIs were added to cell
cultures. 7 Days later, 50 ml of 3-(4, 5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) (1 mg/ml) was added. 4 h
later, MTT was removed and 150 μl of dimethyl sulfoxide (DMSO)
was added. The spectrophotometric absorbance was measured on
a model 550 microplate reader (Bio-Rad Laboratories, Hercules,
CA) at 570 nm with a reference wavelength of 655 nm. Cell
viability was calculated according to the following formula: cell
viability¼absorbance value of infected cells/absorbance value of
uninfected control cells.
Subcutaneous glioma model
Procedures for animal experiments were all approved by the
Committee on the Use and Care on Animals in the Afﬁliated
Hospital of Medical College of Qingdao University (Qingdao,
China).
U-87 MG subcutaneous tumor xenograft was established by
injecting 2106 cells at the left ﬂanks of 5-week-old male BALB/c
nude mice (Institute of Animal Center, Chinese Academy of
Sciences, Shanghai, China). As soon as tumors grew to 6–8 mm
in diameter, 24 mice were randomly and equally divided into
4 groups (n¼6). The mice were intratumorally injected with
100 μL PBS with or without 2108 pfu of Ad-WT, Onyx-015 and
OA-4MREs. The injections were repeated every other day with a
total dosage of 1109 pfu of adenoviruses for ﬁve times.
Primary glioma xenograft was established by incubating
1106 cells at the lower right ﬂanks of 5-week-old male BALB/c
nude mice. 20 mice were randomly divided into 6 groups with
equal number (n¼5). The doses of used adenoviruses were equal
to that for U-87 MG tumor xenograft.
Tumor diameter was measured by periodic measurements with
calipers and volume was calculated using the following formula:
tumor volume (mm3)¼maximal length (mm)perpendicular
width (mm)2/2.
Intracranial glioma model
To establish an intracranial glioma xenograft mouse model, a
previously described procedure was followed (McCutcheon et al.,
2000). Brieﬂy, 1106 U-87 MG cells were injected into the
forebrain of 5-week-old male BALB/c nude mice with the direction
of a guide-screw. 7 Days later, 24 mice were equally divided into
4 groups (n¼6). 1109 pfu of indicated adenoviruses were intra-
tumorally delivered in a single injection. Since then, the mice were
monitored every day for their conditions. The mice were eutha-
nized by carbon dioxide when they showed signs of impending
death. At the same time, the death was recorded to determine
their survival rates.
The Kaplan–Meier method and the Cox–Mantel log-rank test
(two-sided) were used to assess the statistical signiﬁcances of
differences in survival time.
Liver damage evaluation
To evaluate the hepatotoxicity induced by adenovirus treat-
ment, twenty 5-week-old male BALB/c mice were divided into
4 groups (n¼5) and were intravenously injected with 1109 pfu
of indicated adenoviruses every other day for ﬁve times. On day 11,
their blood (600 ml/mice) was harvested by cardiac puncture,
followed by being incubated with 12 U of heparin. Alanine
aminotransferase (ALT) levels in blood were detected at the
Clinical Laboratory, The Afﬁliated Hospital of Medical College of
Qingdao University (Qingdao, China)
Histological staining
On day 7 after adenovirus injection, one mouse from each
group in intracranial tumor models was sacriﬁced and its tumor
and brain were harvested. Liver were obtained from the tumor-
free mice intravenously injected with adenoviruses. Histological
staining was then performed on formalin-ﬁxed, parafﬁn-
embedded samples using the streptavidin–biotin-peroxidase com-
plex method. Mouse monoclonal IgG against adenovirus E1A
protein (1:100; Santa Cruz Biotechnology, CA) was used to speci-
ﬁcally recognize and bind the antigen. Incubation with secondary
antibody (Immunology Consultants Laboratory Inc, OR; 1:100) was
followed and E1A expression was visualized using 3, 30-diamino-
benzidine (Sigma, USA). The sections were ﬁnally counterstained
with hematoxylin.
Statistical analysis
The statistical tests in this manuscript were two-tailed Stu-
dent's t-test. Differences were considered as statistically signiﬁ-
cant (n) when Po0.05 and statistically very signiﬁcant (nn) when
Po0.01, except for the survival analysis on the intracranial glioma
xenograft mouse model.
Appendix A. Supporting information
Supplementary data associated with this article can be found in
the online version at http://dx.doi.org/10.1016/j.virol.2014.04.007.
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